Somewhat Positive Press Coverage Somewhat Unlikely to Affect Mediwound (MDWD) Share Price

Media headlines about Mediwound (NASDAQ:MDWD) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mediwound earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 48.0579643594597 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Mediwound stock opened at $5.25 on Friday. Mediwound has a 52 week low of $3.56 and a 52 week high of $8.25. The company has a market cap of $142.00, a P/E ratio of -5.36 and a beta of 0.15.

Mediwound (NASDAQ:MDWD) last issued its earnings results on Monday, March 19th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.08. The company had revenue of $0.53 million during the quarter, compared to analyst estimates of $0.65 million. Mediwound had a negative net margin of 887.38% and a negative return on equity of 234.12%. equities research analysts predict that Mediwound will post -0.72 earnings per share for the current year.

A number of equities analysts recently commented on MDWD shares. Oppenheimer set a $10.00 price objective on shares of Mediwound and gave the stock a “buy” rating in a research note on Friday, December 8th. Zacks Investment Research raised shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Thursday. Wells Fargo decreased their price objective on shares of Mediwound from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, March 20th. Finally, ValuEngine raised shares of Mediwound from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $9.25.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Mediwound (MDWD) Share Price” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3299587/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-mediwound-mdwd-share-price.html.

Mediwound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Insider Buying and Selling by Quarter for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jewett-Cameron Trading Co  Stake Held by Fort Nelson Partners, LP
Jewett-Cameron Trading Co Stake Held by Fort Nelson Partners, LP
Greenhill & Co.  and GAMCO Investors  Critical Review
Greenhill & Co. and GAMCO Investors Critical Review
STRAKS Tops 1-Day Volume of $24,012.00
STRAKS Tops 1-Day Volume of $24,012.00
KlondikeCoin  Achieves Market Capitalization of $0.00
KlondikeCoin Achieves Market Capitalization of $0.00
Roku  and Its Competitors Head to Head Survey
Roku and Its Competitors Head to Head Survey
Pentair  vs. Metso  Financial Analysis
Pentair vs. Metso Financial Analysis


© 2006-2018 Ticker Report. Google+.